NCT02046655

Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI

Corifollitropin Alfa Compared to Daily Rec FSH in Poor Responders Undergoing ICSI Using a GnRH Antagonist Protocol

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Aristotle University Of Thessaloniki · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Corifollitropin alfa has been shown to result in significantly more oocytes compared to daily recombinant follicle stimulating hormone (recFSH) (Devroey et al., 2009), probably due to the higher circulating FSH activity during the first days of stimulation. For this reason, the use of corifollitropin alfa might be beneficial in poor responders in whom the number of oocytes retrieved is crucial for success. The purpose of this study is to evaluate the effectiveness of corifollitropin alfa treatment compared to daily recFSH in terms of the number of oocytes retrieved in a defined population of poor responder patients undergoing intracytoplasmic sperm injection (ICSI) using gonadotrophin releasing hormone (GnRH) antagonists.

Conditions

• Subfertility

Interventions

Type	Name	Description
DRUG	Corifollitropin alfa
DRUG	rFSH

Timeline

• Start date: 2011-01-01
• Primary completion: 2014-03-01
• First posted: 2014-01-28
• Last updated: 2014-05-14

Locations

1 site across 1 country: Greece